Background

Immune checkpoint inhibitors (ICI), alone or in combination with chemotherapy, have become the standard of care in patients with non-small cell lung cancer (NSCLC) without targetable molecular alterations. However, most patients with lung cancer either do not respond to or do not experience long-term benefits from ICI. There is an urgent need to identify other robust biomarkers predictive of response to ICI and to understand the mechanisms behind lung cancer resistance to immunotherapy.

Technology Overview

Researchers at The Institute of Cancer Research, London, have identified that the expression of ART1 by tumour cells mediates immune resistance in non‑small cell lung cancer (NSCLC) patients – and ART1 inhibition can improve tumour control in preclinical models.

The Institute of Cancer Research